Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Clinical trial NCT06569225 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06569225
- Sponsor
- University Health Network, Toronto
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-15
- Primary completion
- 2027-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.